公开(公告)号：EP4291166A1

公开(公告)日：2023-12-20

申请号：EP22704889.9

申请日：2022-02-03

申请人： Warszawskie Zaklady Farmaceutyczne Polfa S.A.

发明人： KUBISIAK, Marcin ,  PIETRZAK, Tomasz ,  RATAJCZAK, Tomasz ,  SZENDZIELORZ, Ziemowit ,  BORYCHOWSKA, Joanna

IPC分类号： A61K9/19 ,  A61K9/00 ,  A61K9/10 ,  A61K31/496 ,  A61P25/18

公开(公告)号：EP4039248A1

公开(公告)日：2022-08-10

申请号：EP21461508.0

申请日：2021-02-04

申请人： Warszawskie Zaklady Farmaceutyczne Polfa S.A.

发明人： Kubisiak, Marcin ,  Ratajczak, Tomasz ,  Popielska, Iwona ,  Rochowczyk, Anna ,  Magnuszewska, Monika ,  Domel, Izabela

IPC分类号： A61K9/08 ,  A61K47/26 ,  A61K31/728

摘要： The application refers to an ophthalmic composition comprising hyaluronic acid or an ophthalmologically acceptable salt thereof in amount of less than or equal to 2% by weight and not less than or equal to 0.01% by weight, an oligosaccharide in amount of less than or equal to 6% by weight and not less than or equal to 0.1% by weight, and a compound selected from the group consisting of panthenol, pantothenic acid, an ophthalmologically acceptable salt of pantothenic acid, and combinations thereof in amount of less than or equal to 5% by weight and not less than or equal to 0.1% by weight, and an amount of water up to 100% by weight of the composition. The application also refers to the above composition for use in the prevention and/or treatment of an ophthalmological pathology selected from the group consisting of dry eye syndrome, Sjogren syndrome, inflammation of the conjunctiva, irritation, itchiness, burning and allergic reactions of the eye, and related conditions.